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Abstract
Maintenance of corneal transparency is crucial for vision and depends mainly on the endothelium, a non-proliferative
monolayer of cells covering the inner part of the cornea. When endothelial cell density falls below a critical threshold, the
barrier and ‘‘pump’’ functions of the endothelium are compromised which results in corneal oedema and loss of visual
acuity. The conventional treatment for such severe disorder is corneal graft. Unfortunately, there is a worldwide shortage of
donor corneas, necessitating amelioration of tissue survival and storage after harvesting. Recently it was reported that the
ROCK inhibitor Y-27632 promotes adhesion, inhibits apoptosis, increases the number of proliferating monkey corneal
endothelial cells in vitro and enhance corneal endothelial wound healing both in vitro and in vivo in animal models. Using
organ culture human cornea (N= 34), the effect of ROCK inhibitor was evaluated in vitro and ex vivo. Toxicity, corneal
endothelial cell density, cell proliferation, apoptosis, cell morphometry, adhesion and wound healing process were
evaluated by live/dead assay standard cell counting method, EdU labelling, Ki67, Caspase3, Zo-1 and Actin immunostaining.
We demonstrated for the first time in human corneal endothelial cells ex vivo and in vitro, that ROCK inhibitor did not
induce any toxicity effect and did not alter cell viability. ROCK inhibitor treatment did not induce human corneal endothelial
cells proliferation. However, ROCK inhibitor significantly enhanced adhesion and wound healing. The present study shows
that the selective ROCK inhibitor Y-27632 has no effect on human corneal endothelial cells proliferative capacities, but alters
cellular behaviours. It induces changes in cell shape, increases cell adhesion and enhances wound healing ex vivo and
in vitro. Its absence of toxicity, as demonstrated herein, is relevant for its use in human therapy.
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Introduction
Preservation of corneal transparency is essential for vision. This
requires integrity of the three layers of the cornea, the stratified
squamous epithelium, the stroma and the inner surface endothe-
lium. The corneal endothelium is a monolayer of cells, which is
formed from neural crest-derived cells. During development,
corneal endothelial cells (CEC) proliferate and migrate centrally to
form a continuous mosaic of cells, facing the aqueous humor. Cell-
cell contact induces growth arrest in G1 phase through contact
inhibition mechanism, leading to the formation of a monolayer
with a defined endothelial cell density (ECD) [1]. The corneal
endothelium is responsible for the passive diffusion of nutriments
from the aqueous humor and for the hydration of the cornea
through its barrier and ionic pump functions [2]. Several studies
have shown that human endothelial cells do not replicate in vivo,
even if they retain a proliferative potential, as seen in ex vivo wound
healing experiment or in vitro [3,4]. A recent study demonstrated
that a few proliferating cells were found exclusively in extreme
periphery of endothelium on human corneas with a short
postmortem time and that a very slow and continuous centripetal
cell migration might exist to partially compensate the physiological
cell loss in vivo [5]. Nevertheless, this mechanism cannot
immediately compensate neither acute nor chronic important
CEC losses which are replaced by enlargement and migration of
neighboring cells resulting in shape modification and increase of
cell size [6,7]. In physiologic conditions the insufficient pro-
liferative capacity leads to a gradual ECD decrease of 0.3–0.6%
per year [8]. This decrease can be accelerated as a result of
accidental trauma, certain systemic diseases like diabetes [9],
treatment for glaucoma [10] or endothelial dystrophies [11].
When ECD falls below a critical threshold, the barrier and
‘‘pump’’ functions of the endothelium are compromised and this
results in the formation of a corneal oedema and loss of visual
acuity. The conventional treatment for such severe disorder is
corneal transplantation, including penetrating keratoplasty and
endothelial lamellar graft. Human corneas harvesting, evaluation,
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preservation and distribution are under the responsibility of eye
banks, which stores corneal tissue either for short term at 2–6uC
(Cold storage USA and Asia) or for long term at 30–32uC in
culture medium (Organ culture, mostly in Europe). Unfortunately,
there is a worldwide shortage of donor corneas available for
transplantation.
Several approaches have been evaluated to overcome this lack
of tissues. Improvement of surgical procedures allows optimizing
the use of corneal graft, especially by lamellar technique,
according to the principle of split cornea transplantation for two
recipients (anterior and posterior) [12]. In order to extend the EC
viability of organ-culture cornea, an anti-apoptotic gene therapy
was also assessed. Experiments demonstrated that expression of
anti-apoptotic proteins Bcl-xL or p35 allowed limiting the cell loss
and increasing the number of available donor’s corneas. [13].
During the last decades, in vitro culture technics of human corneal
endothelial cells (HCEC) have greatly improved. These cells can
be isolated and expanded in culture either as a monolayer [14] or
as sphere-forming colonies [15] and a number of studies showed
the possibility to transplant them as a cellular sheet with or without
a carrier or by injecting them directly into the anterior chamber in
animal models [16,17]. Medical treatments are also considered in
order to cure corneal endothelial diseases directly in vivo. One
promising target is the Rho family GTPase signalling and its best
characterised downstream effector, Rho-associated, coiled-coil-
forming protein kinase (ROCK). Trough phosphorylation of
myosin light chain (MLC), myosin light chain phosphatase
(MLPC) and LIM kinase (LIMK), ROCK regulates the formation
of actin stress fibers assembly and cell contraction [18]. ROCK
controls also, via phosphorylation of Na+/H+ exchanger 1
(NHE1), the formation of focal adhesion, which linked stress
fibers to the extracellular matrix, an important step involved in cell
adhesion and motility [19]. In addition to these primary functions
in cytoskeleton remodeling and migration, this pathway has been
shown to be involved in the regulation of other biological processes
like gene transcription, G1 cell cycle progression and apoptosis
[20,21]. ROCK inhibitor molecule seems to be promising for the
treatment of a wide-range of pathologies including cancer,
neuronal degeneration, kidney failure, asthma, glaucoma, osteo-
porosis, erectile dysfunction and insulin resistance [22]. In
ophthalmology, this inhibitor has been evaluated in corneal
endothelial cells using rabbit and monkey animal models. This
molecule inhibited dissociation-induced apoptosis and promoted
the adhesion and proliferation of monkey corneal endothelial cells
(CEC) [23]. Furthermore, ROCK inhibitor is able to increase
wound healing process in monkey CEC and in vivo by topical
treatment of rabbits wounded by transcorneal freezing [24].
Recently, it has been shown that modulation of cell adhesion by
ROCK inhibitor allows enhancing EC engraftment in a primate
model of endothelial dysfunction [25], leading to the grant of
a patent application [26].
Here, we proposed to evaluate the effects of ROCK inhibitor on
HCEC in vitro and ex vivo, firstly to assess the potentiality to
increase the number of corneal graft available for eye banks and
secondly to further validate the previous results obtained in animal
models, a step required before first in man application.
In the present study, we demonstrated for the first time on
HCEC that ROCK inhibitor is not toxic, does not induce
proliferation and does not modulate apoptosis. However, it
promotes corneal endothelial wound healing by enhancing
endothelial remodeling, adhesion and cell migration.
Materials and Methods
Materials
Serum-free medium (OptiMEM-1), Petri dish, multiwell tissue
culture plates, fetal bovine serum (FBS) were purchased from
Fisher Scientific (Wohlen, Switzerland). Medium 199 (M199),
epidermal growth factor (EGF; from mouse submaxillary glands),
nerve growth factor (NGF; from mouse submaxillary glands),
bovine pituitary extract (also known as Keratinocyte Growth
Supplement), ascorbic acid, calcium chloride, chondroitin sul-
phate, EDTA (EDTA disodium salt), antibiotic/antimycotic
solution, gentamicin, trypsin and ROCK inhibitor (Y-27632) were
purchased from Sigma-Aldrich (Buchs, Switzerland). Cell attach-
ment reagent (FNC Coating Mix) was purchased from GEN-
TAUR (Brussels, Belgium). TRIzol Reagent, Oligo(dT)12–18
primer, dNTP Mix (10 mM), Ribonuclease H, dithiothreitol
(DTT; 0.1 M), 5X First-Strand Buffer, SuperScriptTM II Reverse
Transcriptase, Click-iTH EdU Cell Proliferation Assays, Zo-1
primary antibody, Alexa Fluor 555/633H and Live/Dead Assay
Kit were purchased from Invitrogen (Zug, Switzerland). Taq PCR
Master Mix was purchased from Qiagen (Hombrechtikon,
Switzerland). ROCK 1 and ROCK 2 forward and reverse
primers were purchased from Microsynth (Balgach, Switzerland).
Ki67 primary antibody and antifading fluorescent mounting
medium were purchased from DakoCytomation (Baar, Switzer-
land). Caspase3 primary antibody was purchased from BD
(Allschwil, Switzerland) and CorneaMax medium from Eurobio
(Les Ulys, France).
Human Corneal Tissue
All procedures conformed to the tenets of the Declaration of
Helsinki for biomedical research involving human subjects. All
study corneas were received from Lausanne Eye Bank, and had
been considered to be unsuitable for transplantation. In accepting
corneas from Lausanne Eye Bank, the overall health of the donor
before death was considered and tissue was rejected from donors
with previous history or treatment that might have damaged the
corneal endothelium. Criteria for exclusion were: too long a period
between time of death and time of preservation, corneas from
donors with diabetes, glaucoma, sepsis, or ocular infection, or from
donors who were on large doses of chemotherapeutic agents. After
retrieval, corneas were placed in 100 ml of CorneaMax at 32uC in
a dry incubator, according to the standard organ-culture (OC) in
Figure 1. mRNA expression of ROCK 1–2 in HCEC ex vivo and
in vitro. Rho kinase (ROCK) 1 and ROCK 2 mRNA are expressed in
human corneal endothelial cells from ex vivo corneas and primary cell
cultures in Low as High Medium.
doi:10.1371/journal.pone.0062095.g001
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Figure 2. Ex vivo toxicity-viability and apoptosis assessment. (A) Toxicity evaluation by Ethidium Homodimer and Hoechst staining. Some
dead cells are present in all conditions. (Magnification 10x.) (B) Mortality rate (%) corresponding to the number of positive Ethidium nuclei out of the
total number of nuclei (Hoechst+Ethidium nuclei). No differences are observed between groups. (C) Relative Endothelial Cell Density (ECD)
corresponding to the ratio between the number of nuclei and the area of the Region Of Interest (ROI). No differences are observed between groups.
ROCK Inhibitor and Human Corneal Endothelial Cells
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place in the Lausanne Eye Bank. For the ex vivo and in vitro studies
17 pairs of OC corneas [mean donor age: 73+/2 SEM 3 years
(median 73; range 47–91); mean time from death to procurement:
18+/21 hours (18; 9–27)] and 7 OC corneas [mean donor age:
79+/24 years (85; 64–86); mean time from death to procurement:
19+/26 hours (19; 2–40)] were used respectively.
Primary Cell Culture
HCEC were isolated and cultured according to published
protocols [27]. Corneas were removed from the conventional OC
medium and washed several times with M199 containing 50 mg/
ml gentamicin before being placed in a Petri dish. Descemet’s
membrane with intact endothelium was carefully dissected in small
strips and then incubated in OptiMEM-I supplemented with 10%
FBS overnight to stabilize the cells before culture. After
(D) Cell viability evaluation by Calcein AM and Hoechst staining. Magnification 4x. (E) Viability rate (%) corresponding to the ratio between the
surface of positive Calcein cells and the field measurement area. No differences are observed between groups. (F) Apoptosis evaluation by Caspase3
immunostaining. Caspase3 positive cells were rarely observed. No differences are observed between groups. (Magnification 40x.) Values are means +/
2 SEM (n= 3 pairs). No differences are observed between groups.
doi:10.1371/journal.pone.0062095.g002
Figure 3. Ex vivo proliferation assessment. (A) Proliferation evaluation by Endothelial Cell Density (ECD) determination. ECD after corneas
procurement is comparable in the control and the treated corneas. A cell loss of 12% and 9% for control and treated corneas respectively is observed
after corneas storage during 14+/22 days with no significant differences between both groups. A similar cell loss is observed in control and Y-27632
treated corneas after 1363 days of preservation with respectively 8% and 9%. The threshold of 2000 cells/mm2 conventionally used to deliver grafts
for penetrating keratoplasty is shown as a green dotted line. Values are means +/2 SEM (n= 6 pairs). (B) Proliferation evaluation by EdU incorporation
and Ki67 immunostaining. Only few EdU and Ki67 positive cells were detected in both groups. (Magnification 40x).
doi:10.1371/journal.pone.0062095.g003
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Figure 4. Ex vivo morphological assessment. (A) Zo-1 immunostaining. In control corneas, endothelial cells appear as a mosaic of cells with
polygonal shape. Addition of Y-27632 induces a morphological change with a loss of the polygonal shape and an irregular cell border, suggesting
a disruption of the tight junctions. (B) Actin staining. In control corneas, actin filaments are assembled into large radial and circumferential bundles,
with a main localization along the membrane of the endothelial cells. After treatment the distribution of F-actin are altered, with only a residual
staining associated with the cell periphery. The formation of circular membrane ruffles of variable size and actin content can also be observed.
doi:10.1371/journal.pone.0062095.g004
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centrifugation, the strips were incubated in 0.02% EDTA solution
at 37uC for 1 hour to loosen cell–cell junctions. Cell junctions
were disrupted by forcing the tissue and medium multiple times
through the narrow opening of a flame-polished pipette. Cells
were peeled and re-suspended in High Medium (HCEC conven-
tional proliferative culture medium) containing OptiMEM-I, 10%
FBS, 5 ng/ml EGF, 20 ng/ml NGF, 100 mg/ml pituitary extract,
20 mg/ml ascorbic acid, 200 mg/l calcium chloride, 0.08%
chondroitin sulphate, 50 mg/ml antibiotic/antimycotic solution
diluted 1/100. Isolated cells and pieces of Descemet’s membrane
that still contained attached cells were plated in 6-well tissue
culture plates that had been precoated with undiluted FNC
Coating Mix. Cultures were then incubated at 37uC in a 5%
carbon dioxide, humidified atmosphere. High Medium was
changed every 2 days. After primary cultures reached confluence,
cells were trypsinized, filtered and seeded at the same number per
well in a 12 well tissue culture plate and stored at 37uC in High
Medium until reach 50% or 100% confluence, depending the
experiments. Cells were then extensively washed with PBS and
treated with ten mM Y-27632 diluted in High Medium or Low
Medium composed of OptiMEM-I plus 4% FBS (mean serum
concentration used by Eye Bank in OC medium). Except for
ROCK1 and ROCK2 mRNA expression, all experiments were
repeated with three different biological samples and performed in
triplicates for each condition.
ROCK 1 and ROCK 2 mRNA Expression in OC and Primary
Culture HCEC
Ex vivo HCEC isolation. Two pairs of OC cornea were used
in order to evaluate the expression of ROCK 1 and ROCK 2
mRNA in HCEC. Under an operating microscope, Descemet’s
membrane with endothelium was peeled off from the underlying
stroma with forceps to avoid contamination by other cell types.
Tissues were then frozen at 280uC until RNA isolation.
In vitro HCEC isolation. Confluent cell cultures (P1) were
washed twice with PBS and then incubated during 2 days in High
or Low Medium. Cells were then trypsinized, pelleted and frozen
at 280uC until RNA isolation. Experiment was performed
independently with two biological samples.
RNA isolation and reverse transcription. Total RNA was
isolated from HCEC using the TRIzol solution according to the
manufacturer’s instructions. First-strand cDNA synthesis was
carried out on 1 mg of total RNA in a final volume of 20 mL
with SuperScriptTM II Reverse Transcriptase as per the
manufacturer’s protocol. Briefly, after addition in nuclease-free
microcentrifuge tubes of 1 mg of total RNA, 0.1 mL Oligo(dT)12–18
(500 mg/ml), 1 mL dNTP Mix (10 mM each) and sterile distilled
water to complete the volume at 12 mL, the mixture was heated at
65uC for 5 minutes. 4 mL of 5X First-Strand Buffer and 2 mL of
DTT were then added and the mix incubated at 42uC for 2
minutes. Incubation at 42uC for 50 minutes was performed after
the addition of 1 mL of SuperScriptTM II RT. The reaction was
inactived by heating at 70uC for 15 minutes. To remove RNA
complementary to the cDNA, 1 mL of E. coli RNase H (two units)
was added and the mixture incubated at 37uC for 20 minutes and
then chilled on ice. cDNA were stored at220uC until use in PCR.
PCR. PCRs were performed using 1 mL of RT products, 2.5
units of Taq DNA Polymerase, 1x PCR Buffer (containing
1.5 mM MgCl2), 200 mM of each dNTP and 0.5 mM of each
primer. The sequences of human ROCK 1, ROCK 2 and
GAPDH primers (Yin, 2008, Friel, 2005) were respectively: sense
59-GAAGAAAGAGAAGCTCGAGA-AGAAGG-39, antisense
59-ATCTTGTAGCTCCCGCATCTGT-39; sense 59-AATT-
CACTGTGTTT-CCCTGAAGATA-39, antisense 59-
TTCATTTTTCCTTGATTGTATGGAA-39 and sense 59-
TGCACCACCAACTGCTTAGC-39; antisense 59-GGCATG-
GACTGTGGTCATGAG-39. Amplifications were carried out
using the following cycling parameters: initial denaturation at
Figure 5. Ex vivo wound healing assessment. Y-27632 induces a totally wound closure after 12+/24 days, while acellular areas could be still
observed in the control group. Treated endothelial cells appear bigger than cells from unwounded region and have a regular shape. A pleomorphism
is detected in the control group. (Magnification 60x).
doi:10.1371/journal.pone.0062095.g005
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95uC for 10 minutes, denaturation at 95uC for 60 seconds,
annealing at 60uC for 60 seconds, and extension at 72uC for 60
seconds. PCR amplification was done for 32 cycles with a final
extension at 72uC for 10 minutes. For negative controls, PCR was
run on RT products performed on water and on samples without
RT enzyme. The PCR products were subjected to electrophoresis
on 1% agarose gels containing SYBRH Safe DNA Gel Stain.
Stained gels were captured using a digital camera.
Toxicity, Viability and Apoptosis Assessment
Ex vivo live/dead assay. In order to determine the effect of
ROCK inhibitor on HCEC viability, live-dead assays were
conducted on three pairs of OC corneas with or without treatment
for 48 hours with ten mM Y-27632. The live/dead assay was
performed according to published protocols [28]. Briefly, after the
48 hours of incubation corneas were washed in PBS, placed
endothelial side up in a sterile Petri dish, incubated for 45 minutes
at 37uC with 100 mL of Hoechst 33342 (10 mM), Ethidium
Homodimer-I (4 mM) and Calcein-AM (2 mM), and then gently
rinsed in PBS. After having done a radial cut on corneas to allow
a flat mount without folding, corneas were mounted endothelial
side up under a coverslip using an antifading agent. Five tagged
image format file images (a central image and one in each quarter)
were acquired using a microscope (BX60; Olympus, Tokyo,
Japan) with a x4 objective for the Calcein and x10 objective for the
Hoechst and Ethidium stainings. Viability, corresponding to the
Calcein staining, was measured on the totally of the 5 images using
the Cell‘P software (Cell‘P; Cell Imaging, Hamburg, Germany).
After background noise removal, signal thresholding, and binar-
ization, the calcein surface area was automatically calculated, as
was the ratio of viable surface area to total analyzed area. In
determined Region Of Interest (ROI) of the five images, all the
positive Hoechst and Ethidium nuclei were counted. The
mortality rate was the number of positive Ethidium nuclei out of
the total number of nuclei (Hoechst+Ethidium). Relative ECD in
the selected areas corresponded to the ratio between the number
of nuclei and the delineated measurement area. The mean of the
five images was considered.
In vitro live/dead assay. In order to test the effect of Y-
27632 treatment on HCEC viability, studies were conducted using
P1 confluent and non-confluent HCEC cultures. Cells in a 12-well
tissue culture plate were extensively washed with PBS and treated
2 days with ten mM Y-27632 diluted in High or Low Medium.
The cell-viability assay, as described previously, was performed to
determine overall viability. Three randomly selected images per
well were acquired using a microscope with a x10 objective for the
three staining. Mortality, Relative ECD and Viability were
determined as described previously. Cells fixed in absolute
methanol for 10 minutes at 220uC before staining were used as
positive control. All experiments were repeated with three different
biological samples and performed in triplicates for each condition.
Ex vivo and in vitro apoptosis assessment. In order to
determine the involvement of Y-27632 on HCEC apoptosis,
Caspase3 immunostaining was performed on three pairs of OC
corneas after treatment with ROCK inhibitor. Briefly, corneas
were fixed with 4% PFA, blocked and permeabilized in 3% BSA,
1% Triton X-100. Corneas were incubated with Caspase3
primary antibody (1:50) at RT for 2 hours and then incubated
with a 1:500 dilution of the Alexa Fluor 633H-conjugated
secondary antibody. To assess specificity of the immunostaining,
corneas were processed without primary antibody. Nuclei were
counterstained with DAPI and corneas flat mounted side up under
a coverslip using an antifading mounting medium. The apoptosis
Figure 6. In vitro toxicity-viability and apoptosis assessment. (A) Toxicity and viability evaluation by triple staining Hoechst (nuclei) Ethidium
(dead cells) and Calcein (viable cells). Methanol-fixed cultures act as positive controls for cell death. Few dead cells are present in all conditions and
Calcein staining shows no differences in the cell viability after Y-27632 treatment. (B) Mortality rate (%) corresponding to the number of positive
Ethidium nuclei out of the total number of nuclei (Hoechst+Ethidium nuclei). No differences are observed between all groups. (C) Relative Endothelial
Cell Density (ECD) corresponding to the ratio between the number of nuclei and the Region Of Interest (ROI) measurement area. No differences are
observed between all groups. (D) Apoptosis evaluation by Caspase3 immunostaining. No staining is observed in all groups. (Magnification 10x).
Values are means +/2 SEM (n= 9).
doi:10.1371/journal.pone.0062095.g006
Table 1. Toxicity assessment on confluent primary cell culture.
Mortality (%) Low medium control High medium control Low medium+Y-27632 High medium+Y-27632
Mean+/2SEM 0.14+/20.07 0.08+/20.05 0.14+/20.07]) 0.07+/20.07
Low medium control
(P value)
0.44 0.98 0.43
High medium control
(P value)
0.46 0.90
Low medium+Y-27632
(P value)
0.44
Relative ECD (%) Low medium control High medium control Low medium+Y-27632 High medium+Y-27632
Mean+/2SEM 876+/247 987+/291 811+/242 842+/233
Low medium control
(P value)
0.60 0.39 0.67
High medium control
(P value)
0.14 0.30
Low medium+Y-27632
(P value)
0.30
doi:10.1371/journal.pone.0062095.t001
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assessment was also performed on confluent primary cell cultures
(P1) after Y-27632 treatment. Cells were subcultured in High
Medium until reached 100% confluence. Cells were then
extensively washed with PBS and treated 2 days with ten mM Y-
27632 diluted in High Medium or Low Medium. Caspase3
immunolocalization in cultured cells was performed with the same
protocol as described above. Staining was visualized using
a fluorescence microscope.
Proliferation Assessment
Ex vivo. Proliferation assessment was evaluated by three
methods: (1) Routine CEC count usually performed in the
Lausanne Eye Bank (2) Click-iTH EdU Cell Proliferation Assays
(3) Ki67 immunostaining, which has been proven as a reliable
proliferation cell marker for ex vivo and in vitro HCEC [29]. Six
pairs of OC corneas were used for the proliferation assessment.
Standard endothelial cell count. After washing in BSS,
corneas were placed endothelial side up in a sterile Petri dish.
Dead cells were identified using 0.4% trypan blue only, to
eliminate corneas with extensive CEC necrosis. The endothelial
surface was incubated with 0.9% sodium chloride for 4 minutes to
dilate the intercellular spaces. Once the cell contours were
optimally discernible, the endothelium was viewed through a long
working distance x10 objective using a light direct microscope and
endothelial photographs were acquired. ECD was determined
manually on three randomly chosen non-adjacent zones of the
endothelium contained within the central 8 mm diameter. This
ECD evaluation was performed three times: (1) just after corneas
procurement (2) just before ten mM Y-27632 addition in OC
medium after a mean storage time of 14+/22 days and finally (3)
after a supplemental time of conservation of 13+/23 days.
Click-iTH EdU cell proliferation assays. Ten mM EdU
was added to the medium at the same time as Y-27632, detection
was performed. HCEC that had integrated EdU during S phase
were detected as follows. Briefly, Corneas were washed twice with
PBS and fixed with 4% PFA at room temperature (RT) for
30 min. Following fixation, corneas were washed twice with 3%
BSA and treated with 1% Triton X-100 at room temperature for
20 min. After permeabilization, corneas were washed twice with
3% BSA. The corneas, placed endothelial side up in Petri dish,
were incubated at room temperature in the dark for 30 min with
100 mL Click-iT reaction mixture (16 Click-iT reaction buffer,
CuSO4, Alexa Fluor 488H-azide, and reaction buffer additive).
Corneas were washed once with 3% BSA and twice with PBS.
Nuclei were counterstained with DAPI and corneas flat mounted
under a coverslip using an antifading agent. Observation was
performed under fluorescence microscope (BX60; Olympus,
Tokyo, Japan). Five images (a central and one in each quarter)
were acquired with a x10 objective. The mean of the five images
was considered.
Ki67 immunostaining. Three of the six corneas pairs used
previously for the EdU assay were evaluated. After EdU
revelation, corneas were washed three times with PBS and
incubated in 3% BSA, 1% Triton X-100 in PBS for 30 min at RT
in order to reduce nonspecific background staining and to
permeabilize cells. Corneas were then incubated with Ki67
primary antibody (1:100) at RT for 2 hours. Following primary
antibody incubation, corneas were washed with PBS, incubated
for 10 min with blocking buffer, and then incubated for 1 hour
with a 1:500 dilution of the Alexa Fluor 633H-conjugated
secondary antibody. Corneas were mounted endothelial side up
under a coverslip using an antifading agent after counterstaining of
the nuclei with DAPI. Positive staining was visualized using the
same fluorescence microscope. To assess specificity of the staining,
corneas were processed without primary antibody.
In vitro. Treatment conditions included the following: (1)
incubation of cells in High Medium without Y-27632; (2)
incubation of cells in High Medium with Y-27632; (3) incubation
of cells in Low Medium without Y-27632, or (4) incubation of cells
in Low Medium with Y-27632. After primary cultures reached
confluence, cells were trypsinized, filtered and seeded at the same
number per well in a 12-well tissue culture plate and incubated 24
hours at 37uC in High Medium to ensure attachment to the
matrix. Cells were further extensively washed with PBS and
treated with ten mM Y-27632 diluted in High or Low Medium
supplemented with ten mM EdU until confluence. Medium was
changed every 2 days. HCEC proliferation kinetic was observed
every day until cells reach confluence under microscope. Pro-
liferation was assessed by Click-iTH EdU Cell Proliferation Assays
and by Ki67 immunostaining as describe previously for the ex vivo
proliferation evaluation. Proliferation was also assessed, in vitro by
the determination of the relative ECD. In determined region of
interest (ROI) of the five images, all the positive EdU cells and
DAPI nuclei were counted. The % of EdU+ cells rate was the
number of positive EdU cells out of the total number of nuclei.
The mean of the five images was considered. Observation was
performed with a microscope (Axiovert 200; Zeiss, Oberkochen,
Germany).
Morphological Assessment
HCEC morphology was evaluated on ex vivo corneas and in vitro
after Y-27632 treatment using zona occludens and actin staining
with respectively Zo-1 antibody and phalloidin. Briefly, corneas
and confluent cells culture (P1) were fixed with 4% PFA, blocked
and permeabilized in 3% BSA 1% Triton X-100. Corneas and
HCEC culture were incubated with Zo-1 primary antibody (1:100)
at RT for 2 hours, washed with PBS and incubated with a 1:500
dilution of the Alexa Fluor 488H or 633H-conjugated secondary
antibodies. For actin staining, corneas and cell cultures were
incubated 1 hour at RT with a 1:200-dilution Alexa Fluor 488H
phalloidin in the dark. Nuclei were counterstained with DAPI and
corneas flat mounted side up under a coverslip using an antifading.
Staining was visualized using a fluorescence microscope for the ex
vivo samples and for cell cultures.
Figure 7. In vitro proliferation assessment. (A) Cell growth kinetic in Low or High Medium supplemented or not with Y-27632. Cells reach
confluency more quickly in High Medium than in Low Medium. Cell shape in the two medium is different, with bigger cells and a more regular
endothelial mosaic in Low Medium than in the High Medium where a poly and pleiomorphism are detected. Y-27632 addition induces modifications
in cell proliferative potential and morphology. In both mediums, cells adopt a fibroblastic-like appearance. Additional time is necessary for cells to
reach the confluency in the presence of Y-27632 whatever the medium. (B) Proliferation evaluation by EdU incorporation and Ki67 immunostaining.
EdU and few Ki67 positive cells are detected in both groups. Magnification 10x. (C) Proliferation rate (%) corresponding to the number of positive EdU
nuclei out of the total number of nuclei (EdU+Dapi nuclei). Globally no differences are noted between all groups, a light statistically significant
decreased in EdU positive cells is observed between control and treated cells incubated in High Medium. (D) ECD in High Medium is higher than in
Low Medium condition as well in the untreated as treated groups. A decreased of the ECD is observed in cells incubated in Low (215%) and High
Medium (222%) supplemented with Y-27632 compared to the controls. Values are means +/2 SEM (n= 9). *P,0.05 and ***,0.0001 (Student’s t-
test).
doi:10.1371/journal.pone.0062095.g007
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Wound Healing Assessment
Ex vivo. A calibrated endothelial wound, using a 10 mL
plastic pipette tip, was performed on whole corneas center (n = 3
pairs) and ten mM Y-27632 was added to the OC medium of one
cornea of each pair. For detection of proliferation, ten mM EdU
was added in OC medium at the same time than Y-27632.
Corneas were then stored at 32uC in a dry incubator. Every day
wound healing was observed after corneas incubation with 0.9%
sodium chloride under light microscope until closure. Alizarin red
staining was performed on corneas after totally wound closure of
the first cornea, either control or treated samples, and HCEC
observed under microscope.
In vitro. HCEC were cultured at confluence in 12-well
culture plates in High Medium (P1). Cells were washed in PBS and
scraped with a 10 mL plastic pipette tip. Cells in suspension were
washed off with PBS. The culture medium was then replaced with
High or Low Medium containing ten mM Y-27632 and ten mM
EdU. The wound distance, that is, the distance between the cells
existing at one edge of the linear defect and those existing at the
opposite edge of the defect, was then determined by use of Cell‘P
software after 0, 2, 4, 6, 8, 10, 12 and 24 hours of incubation.
Proliferation and relative ECD was also assessed by respectively
the % of EdU positive cells and the number of DAPI positive
nuclei per region of interest as described previously.
Cell Adhesion Assay
The adhesion of HCEC to FNC was tested as described
elsewhere [30]. Confluent primary cultured cells (P0) were washed
twice with PBS and then pretreated 30 min with High Medium or
Low Medium supplemented or not with ten mM Y-27632. Cells
were trypsinized, resuspended in their corresponding culture
medium, filtered and adjusted to an equal cell number of 2*105/
ml. Fifty ml of cell suspension was added per well into a 96-well
plates that had been precoated. Cells were allowed to adhere to
the matrix for 2 or 6 hours; nonadherent cells were then washed
off with PBS. Cells were fixed with 4% paraformaldehyde for 10
minutes at RT and stained with 0.1% crystal violet solution for
60 min. Plates were extensively washed with water to remove
excessive staining, and the dye was solubilized with 10% acetic
acid. Absorbance at 570 nm was quantified on a microplate reader
(MRX II; Dynex Technologies). Adhesion morphology was also
assessed on HCEC cultures by actin staining. As described earlier,
cells treated or not with Y-27632 were allowed to adhere to the
FNC coating for 6 hours and nonadherent cells were then washed
off with PBS. Actin was directly stained with Alexa Fluor 488H
phalloidin and cells observed under fluorescence microscope as
described previously.
Statistical Analysis
All data are presented as the mean +/2 SEM. Statistical
significance was determined with Student’s t test or with two way
Anova test. P,0.05 indicated a significant difference.
Results
Presence of ROCK 1 and ROCK 2 Transcripts in HCEC Ex
vivo and In vitro
As shown in Figure 1, the mRNAs for ROCK 1 and 2 were
detected in HCEC in all tested conditions.
Ex vivo Toxicity, Viability and Apoptosis Assessment
The endothelium of control and treated corneas showed only
a few red nuclei (Ethidium Homodimer positive HCEC) indicating
dead cells (Figure 2A). Means mortality were not significantly
different (P = 0.9) between both groups with respectively 1.2+/
20.4% and 1.3+/20.4% of dead cells (Figure 2B). Relative ECD
was also assessed in order to evaluate Y-27632 cytotoxicity. No
statistically significant difference was observed between groups
with 2919+/2274 and 3153+/2277 cells/ROI area (P= 0.36) for
control and treated corneas respectively (Figure 2C). The
endothelium of both groups showed also mainly green fluores-
cence (Calcein-AM), indicating live cells (Figure 2D). No
statistically significant differences between control and treated
corneas were observed (P = 0.6961) with respectively 87.4+/
21.3% and 86.7+/21.2% of Calcein positive staining on the
corneal surface (Figure 2E). Finally, the HCEC apoptosis status
was examined by activated caspase3 immunostaining. Only few
cells in both groups were caspase3 positive as shown in the
Figure 2F. ROCK inhibitor had no acute cytotoxic and did not
trigger apoptosis in HCEC.
Ex vivo Proliferation Assessment
Effects of Y-27632 on ex vivo HCEC proliferation were firstly
evaluated by routine endothelial cell count (Figure 3A). Endothe-
lial baseline characteristics after corneas procurement were
comparable, with 2171+/2189 in the control and 2043+/2162
cells/mm2 in the treated corneas (P = 0.62). After corneas
preservation in OC medium during 14+/22 days, ECD were
1899+/2148 vs. 1898+/2225 cells/mm2 (P= 0.99), correspond-
ing to non-significant cell loss of 12% and 9% for control and
treated corneas respectively. After Y-27632 treatment and OC
preservation during 13+/23 days, final ECD were 1709+/2109
vs. 1736+/2141 cells/mm2 (P= 0.88), corresponding to non-
significant cell loss of 8% and 9% for control and treated corneas
respectively. This ECD decrease in both groups before and after
ROCK inhibitor treatment can be correlated to the mean cell loss
generally observed during OC.
Effects of Y-27632 on ex vivo HCEC proliferation were also
assessed by EdU incorporation and Ki67 immunostaining
(Figure 3B). Few EdU and Ki67 positive cells were detected in
control corneas confirming the low HCEC proliferative status ex
vivo. No differences in the two proliferation markers staining
between Y-27632 treated cells and controls could be observed,
confirming ECD results. Endothelial cells proliferative capacities ex
vivo are insufficient to compensate the daily cells loss, explaining
the ECD decrease. ROCK inhibitor has no effect on the HCEC
proliferative activity in OC corneas.
Figure 8. In vitro morphological assessment. (A) Zo-1 immunostaining reveals a continuous or partially segmented expression at intercellular
junction in both conditions. This expression pattern is completely lost after Y-27632 addition in Low or High Medium culture with more diffuse
intracellular staining. (B) Actin staining reveals radial and circumferential actin bundles in control groups. Y-27632 induces cytoskeleton
reorganization, characterized by a redistribution of actin microfilament on the periphery of the cells and apparition of some membrane ruffles.
(Magnification 40x) (n = 9).
doi:10.1371/journal.pone.0062095.g008
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Ex vivo Morphological Assessment
The effect of ROCK inhibitor on the morphology of HCEC ex
vivo was then examined. Without treatment, HCEC appeared as
a mosaic of cells with polygonal shape. They were characterized
by tight junctions surrounded the entire plasma membrane with
regular expression of Zo-1, a member of a submembranous
cytoplasmic complex associated with tight junctions. Addition of
Y-27632 in the OC medium induced a morphological change with
a loss of the polygonal shape and an irregular cell border,
suggesting a disruption of the tight junctions as shown by the
expression pattern of Zo-1 (Figure 4A).
In order to examine the cytoskeleton structure, phalloidin was
used to investigate the distribution of actin filament in cells. In
control corneas, actin filaments were assembled into large radial
and circumferential bundles, with a main localization along the
membrane of the endothelial cells. After treatment with ten mM Y-
27632, the distribution of F-actin was dramatically altered, with
only a residual staining associated with the cell periphery. The
formation of circular membrane ruffles of variable size and actin
content could also be observed in the endothelium of treated
corneas (Figure 4B). Inhibition of Rho-ROCK pathway in corneal
endothelium induces rearrangement of cytoskeleton.
Ex vivo Wound Healing Assessment
Y-27632 was then evaluated as an enhancer of endothelial
wound healing ex vivo. Treatment with ten mM Y-27632 induced
a totally wound closure after 12+/24 days, while acellular areas
could be still observed in the control group (Figure 5). Even if, as
previously described, EdU positive cells were detected in periphery
of the wound [31], no proliferation differences could be seen
between treated and control cornea (data not shown). These
results demonstrated that ROCK inhibitor has enhanced endo-
thelial wound healing ex vivo, likely due to increased migration and
not proliferation.
In vitro Toxicity, Viability and Apoptosis Assessment
Representative micrographs of the cell-viability assay are
presented in Figure 6A. For this assay, methanol-fixed cultures
acted as positive controls for cell death. Fluorescence microscopy
of methanol-fixed cultures revealed red-stained nuclei throughout
the culture. A small percentage of dead cells were observed in
confluent primary cultures in the different incubation conditions
(Figure 6B). As shown in Table 1 no statistically significant
differences in the cell mortality were observed between all groups.
Such as in the ex vivo study, relative ECD was assessed in order to
evaluate Y-27632 cytotoxicity (Figure 6C). Again, no statistically
significant differences were observed between the different groups
(Table 1). Furthermore, Calcein staining showed no differences in
the cell viability after Y-27632 addition in Low or High Medium
culture indicating that all cells conserved esterase activity
(Figure 6A). In order to evaluate the apoptotic action of ROCK
inhibitor on endothelial cell culture, caspase3 immunostaining was
performed. Regardless of the incubation conditions no caspase3
positive cells were observed (Figure 6D). Similar results were
obtained on non-confluent primary cell culture (data not shown).
These results demonstrated that, like in ex vivo study, Y-27632 had
no acute cytotoxic on HCEC.
In vitro Proliferation Assessment
Proliferation kinetic was evaluated by cell density and EdU
incorporation every day until cells reached confluency with or
without Y-27632 addition in Low and High Medium. A difference
in cell proliferation could be observed between the different
groups. As shown in Figure 7A, cells reached confluency more
quickly in High Medium than in Low Medium demonstrating, as
expected, that High Medium is better to expand HCEC.
Furthermore, cell shape in the two mediums were different, with
bigger cells and a more regular endothelial mosaic in Low
Medium, comparable to the in vivo structure, than in the High
Medium where a pleomorphism was detected. The addition of Y-
27632 induced also some modifications in cell proliferative
potential and morphology. In both mediums, cells adopted
a fibroblastic-like appearance suggesting a higher capacity to
migrate than to proliferate. Indeed additional time was necessary
for cells to reach the confluency in the presence of Y-27632
whatever the medium, demonstrating a reduction of the HCEC
proliferative capacity. These results were also evaluated by Ki67
immunostaining and EdU incorporation assay on HCEC at
confluency (Figure 7B). Only few Ki67 positive cells were detected
in all conditions, which showed a low cell proliferative capacity of
HCEC at confluency. Even if, as presented in Figure 7C, globally
no differences were noted between all groups, a statistically
significant, but low decrease in EdU positive cells was observed
between control and treated cells incubated in High Medium with
respectively 93.6+/21.6% and 91.4+/20.9% of EdU positive
cells (P = 0.02). Relative ECD was also assessed to estimate the
effect of ROCK inhibitor on the HCEC proliferative ability
(Figure 7D). ECD in High Medium condition was higher than in
Low Medium, either untreated or treated, with respectively 852+/
224 vs. 569+/233 cells/ROI area in control culture (P,0.0001)
and 658+/215 vs. 482+/223 cells/ROI area in treated culture
(P,0.0001). In addition, a significant decreased of the ECD (-
22%) was noted in cells incubated in High Medium supplemented
with Y-27632 compared to the control (P,0.0001). A similar, but
not significant, decrease of the ECD (-15%) was observed in Low
Medium culture with ROCK inhibitor compared to Low Medium
control condition. These results indicate that High Medium was
better than Low Medium for HCEC cultivation and inhibition of
Rho-ROCK pathway reduced cell proliferation capacity of
HCEC in vitro.
In vitro Morphological Assessment
As for ex vivo experiment, the effect of ROCK inhibitor on
HCEC was examined in vitro. In untreated culture, Zo-1
immunostaining revealed a continuous or partially segmented
expression at intercellular junction in both conditions. This
expression pattern was completely lost after Y-27632 addition in
Low or High Medium culture with more diffuse intracellular
staining, suggesting a disruption of the tight junctions as already
seen in OC corneas (Figure 8A). To evaluate whether the actin
structure was also affected in vitro, phalloidin staining was
Figure 9. In vitro wound healing kinetic. (A) Representative micrographs of the wound healing kinetic. Wounds are totally closed whatever the
conditions incubation after 24 hours. Compared to controls, Y-27632 enhances endothelial wound closure and cells adopt a fibroblastic-like
appearance 6 hours after treatment. Magnification 10x. (B) Relative wound closure kinetic. Y-27632 significantly increases endothelial wound closure
compared to controls (P = 0.0004). Globally no differences are observed between the Low and the High Medium in the wound healing process. a-d:
P,0.05; a: Low Medium Control vs. Low Medium +Y-27632; b: High Medium Control vs. High Medium +Y-27632; c: Low Medium Control vs. High
Medium Control; d: Low Medium +Y-27632 vs. High Medium +Y-27632 (2way Anova test; n = 9).
doi:10.1371/journal.pone.0062095.g009
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performed in the different conditions of culture. Without Y-
27632, the distribution of actin was mainly the same as for ex
vivo cornea, with radial and circumferential actin bundles.
Treatment with Y-27632 induced cytoskeleton reorganization,
characterized by a redistribution of actin microfilament on the
periphery of the cells and apparition of some membrane ruffles.
Figure 10. In vitro proliferation assessment during wound healing. (A) EdU incorporation evaluation during wound healing process. EdU
staining can be observed in all conditions. Magnification 10x. (B) Proliferation rate (%) corresponding to the number of positive EdU nuclei out of the
total number of nuclei (EdU+Dapi nuclei). High Medium increases EdU incorporation compared with Low Medium in control cultures but also in Y-
27632 treated cultures during wound healing process. Furthermore, Y-27632 treatment decreases the number of EdU positive cells compared to
control groups with a decrease of 23.6 and 30.7% in Low and High Medium respectively. (C) Relative ECD corresponding to the ratio between the
number of nuclei and the ROI measurement area. Cells incubated in High Medium have a superior Relative ECD in control and treated group
compared with cells incubated in Low Medium of respectively 26.4% and 29.6%. Y-27632 treatment decreases the Relative ECD of 17.9% in Low
Medium and of 14.2% in High medium compared to controls. Values are means +/2 SEM (n= 9). **P,0.001 and ***P,0.0001 (Student’s t-test).
doi:10.1371/journal.pone.0062095.g010
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This redistribution of actin was seen in High and Low medium
(Figure 8B).
In vitro Wound Healing Assessment
To determine the role of Rho pathway in endothelial wound
healing, we assessed the effects of Y-27632 on endothelial wound
closure of HCEC monolayer. Confluent culture cells were scraped
with a pipet tip to create cell-free wounds. Cells were then
incubated in Low or High Medium supplemented or not with Y-
27632. Wound healing was observed every 2 hours until 12 hours
and after 24 hours post-wound. Representative micrographs of the
wound healing kinetic are presented in Figure 9A. Compared to
controls, Y-27632 significantly enhanced endothelial wound
closure (P,0.001). Globally no differences were observed between
the Low and the High Medium in the wound healing process.
Wounds were totally closed whatever the conditions after 24 hours
(Figure 9B). To confirm the cell migration involvement in wound
closure and not the cell proliferation, EdU was added at the same
time than Y-27632 and revealed after 24 hours when wounds were
totally closed (Figure 10A). As presented in Figure 10B and
Table 2, large differences can be observed between groups. High
Medium increased EdU incorporation compared with Low
Medium (P,0.0001) in control cultures but also in Y-27632
treated cultures (P,0.0001) during wound healing process.
Furthermore, Y-27632 treatment decreased the number of EdU
positive cells compared to control groups with a decrease of 23.6
and 30.7% in Low and High Medium respectively (P,0.0001).
Relative ECD was also assessed in order to indirectly evaluate the
involvement of Y-27632 on cell proliferation during the wound
healing in vitro (Figure 10C and Table 2). An effect of the medium
could be observed on the relative ECD in the control and treated
group. Cells incubated in High Medium had a superior Relative
ECD in control and treated group compared with cells incubated
in Low Medium of respectively 26.4% and 29.6%. Y-27632
treatment decreased the Relative ECD of 17.9% in Low Medium
and of 14.2% in High medium compared to controls. These results
demonstrated that ROCK inhibitor promotes corneal endothelial
wound healing in vitro by inducing cell motility and not cell
proliferation.
In vitro Cell Adhesion Assay
We next determined whether Y-27632 might play a role in cell
adhesion in HCEC. As shown in Figure 11A, no differences were
observed between the different groups after 2 hours of incubation.
After 6 hours a significantly higher number of HCEC adhered
onto fibronectin matrix compared with lower incubation time
(P,0.0001). Treatment of HCEC with Y-27632 enhanced in
a significant manner cells adhesion after 6 hours compared to
control medium (P,0.05). It can be also noted that medium (Low
or High) was not involved in cell adhesion process (P.0.05). As
already described above, phalloidin staining showed actin
remodelling after ROCK inhibitor treatment, suggesting that
adhesion enhancement could be due to cytoskeleton reorganiza-
tion through Rho signalling pathway (Figure 11B).
Discussion
Loss of visual acuity, following corneal endothelial dysfunction,
is one of the major indications for corneal transplantation. Corneal
grafts are retrieved and evaluated by eye bank before to be use in
clinics and the main criteria for clinical eligibility of cornea is the
ECD. It is representative of the functional capacity of the
endothelium and a minimal density of 2000 cells/mm2 is required
for corneal transplantation. Due to the incapacity of HCEC to
proliferate ex vivo, loss of HCEC during OC is the main reason for
corneal rejection by tissue banks. This ECD decrease seems to be
principally due to apoptosis during storage process [32]. Due to
the shortage of donor corneas available for transplantation, several
groups tried to limit this ECD decrease, either by restraining the
cell loss or by inducing proliferation of the endothelial cell layer.
Using animal models either in vivo or in vitro, Kinoshita and
colleagues have evaluated the role of ROCK inhibitor in CEC.
They have shown that treatment of cynomolgus monkey cultivated
CEC with selective ROCK inhibitor Y-27632 inhibited apoptosis
and promotes proliferation [23]. These data suggest that ROCK
inhibitor is able to modulate apoptosis and proliferation of monkey
corneal endothelial cells in vitro. If this is also true in human, this
inhibitor could be a potential pharmacological compound in order
to optimize eye banking system. As one of the main goals of eye
bank is to avoid the decrease of ECD during storage, addition of
Table 2. % EdU positive cells and relative ECD after wound healing in vitro.
EdU (%) Low medium control High medium control Low medium+Y-27632 High medium+Y-27632
Mean+/2SEM 39.09+/22.07 78.33+/22.09 29.85+/21.46 54.29+/22.73
Low medium control
(P value)
,0.0001 0.0021
High medium control
(P value)
,0.0001
Low medium+Y-27632
(P value)
,0.0001
Relative ECD (%) Low medium control High medium control Low medium+Y-27632 High medium+Y-27632
Mean+/2SEM 1432+/261 1945+/272 1175+/248 1669+/231
Low medium control
(P value)
,0.0001 0.0043
High medium control
(P value)
0.0029
Low medium+Y-27632
(P value)
,0.0001
doi:10.1371/journal.pone.0062095.t002
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ROCK inhibitor could allow limiting the cell loss by its anti-
apoptotic activity and/or increasing ECD by enhancement of cell
proliferation.
In the present study, we first evaluated the toxicity of Y-27632 ex
vivo. We demonstrated that this compound had no toxicity effect
and did not modulate viability of HCEC, suggesting that this
molecule is safe to be used in eye bank or in clinic. However, in
Figure 11. In vitro cell adhesion assay. (A) No differences in cell adhesion are observed between the different groups after 2 hours of incubation.
After an incubation of 6 hours a higher number of HCEC adheres onto fibronectin matrix compared with lower incubation time. Y-27632 enhances
cells adhesion after 6 hours compared to control medium. Medium (Low or High) is not involved in cell adhesion process. Values are means +/2 SEM
(n = 9). *P,0.05 (Student’s t-test). (B) Micrographs of Phalloidin staining. An actin remodeling after ROCK inhibitor treatment can be observed.
(Magnification 40x) (n = 9).
doi:10.1371/journal.pone.0062095.g011
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contrast to a previous report on animal models [23], ROCK
inhibitor treatment was not able to induce proliferation or to
reduce apoptosis ex vivo, as shown by EdU incorporation, as
demonstrated by the ECD loss observed during storage and by
Caspase3 immunostainig. HCEC has been shown to possess
proliferative capacity, but in vivo conditions seem to contribute to
maintenance of a non-replicative monolayer. Several factors are
involved in these antiproliferative mechanisms, including TGF
beta 2 in aqueous humor and a high contact inhibition present in
the corneal endothelial mosaic mediated by the cyclin kinase
inhibitor p27Kip1 [33]. In absence of these factors, HCEC can be
induced to growth in culture. This first result demonstrated that
treatment with Y-27632 was not strong enough to induce
proliferation and to overcome these antiproliferative mechanisms
induced by contact inhibition ex vivo. As ROCK inhibitor has been
shown to induce proliferation of rabbit and monkey CEC in vitro,
we also evaluated the effect of Y-27632 in human primary cell
culture. As per ex vivo evaluation, treatment with ROCK inhibitor
did not show any toxicity on HCEC, demonstrating a potential
safe use of this compound for cell culture. However, inhibition of
Rho-ROCK pathway did not induce proliferation of HCEC as it
was the case for rabbit and monkey endothelial cells, but actually
reduced cell proliferation capacity of HCEC in vitro. These
findings rather confirmed previous studies demonstrating that
inhibition of ROCK signaling induced a reduction of proliferation
of different cell type, including corneal epithelial cells [30],
vascular smooth muscle cell [34], cardiomyocytes [35] and
myofibroblast [36]. These first results demonstrated that ROCK
inhibitor, although non-toxic for the HCEC, will not be the key
factor which allows a greater number of human corneal grafts to
become available clinically or which promotes cultivation of
HCEC.
This unpredicted difference in induction of proliferation could
be explained by the effect of donor age on HCEC proliferative
capacity. It has been shown that cultivated HCEC from older
donors had lower proliferative potential than those derived from
younger donors. This lower potential seems to be due to the
significant increase with age of two cyclin kinase inhibitors,
p21Cip1 and p16INK4, which are important negative regulator of
G1-phase of the cell cycle [37]. In our study the mean donor’s age
was 73 years old and could be considered as old donors, whereas
animals used for the experiment are generally young and would
rather correspond to young donors. Even if younger samples will
be difficult to obtain (average donor age in the eye bank in
Lausanne was 69 years old in 2010), it would be interesting to
evaluate the effect of ROCK inhibitor on HCEC coming from
young donors ex vivo and in vitro. This study will allow evaluating
definitively, whether there is a difference between the action of Y-
27632 in young and old HCEC and so whether ROCK inhibitor
could have an effect on the proliferation induction of some young
populations of HCEC.
Variation has been also observed between species related to
proliferative capacity. Bovine, rabbit and rat endothelial cells grow
easily in culture, whereas monkey and human do not. Culture
rabbit and human cells have been used to compare corneal
endothelial cell cycle and differential expression of cell cycle-
related proteins has been evaluated. The only observed difference
is the localization of cyclin E, which is located in the cytoplasm of
rabbit cells and in the nucleus of human cells [38]. Furthermore,
another study has shown that FGF-2-mediated cell proliferation is
differentially regulated in rabbit and human corneal endothelial
cells. Even if the principal step is mediated by phosphorylation and
degradation of p27kip1 in both species, this induction of pro-
liferation involved PI3-kinase-dependent ERK1/2 activation in
human, while this effect is induced by these two pathways in
parallel and independently in rabbit [39]. These results suggest
that cells derived from rabbit and human are arrested and/or
regulated at different point within G1-phase. It could be possible
that the action of the ROCK inhibitor related to the activation of
the cell cycle is different in human and in animal models,
explaining why such a difference is observed in term of induction
of proliferation.
Besides this induction of proliferation, Kinoshita and colleagues
have demonstrated that ROCK inhibitor promoted in vitro
wound healing of cultivated monkey CEC and administrated as
an eye drop, enhanced corneal endothelial wound healing in
a rabbit model, damaged by transcorneal freezing [24]. The same
group has also observed that injection of cultivated CEC treated
with ROCK inhibitor enables regeneration of cornea in a rabbit
or monkey corneal endothelial dysfunction model. Even if
a previous study reported that cell injection in anterior chamber
was ineffective, as the cells appears to be wash off by aqueous
humor flow [40], they suggested that the injection of cultivated
HCEC in presence of Y-27632 could be a potential therapeutic
strategy in order to cure corneal endothelial dysfunction [25].
Although promising in animal models, the effect of ROCK
inhibitor on wound healing and adhesion was never tested in
human endothelial cornea. Evaluation of this compound in human
cornea will be an essential step before clinical application. In our
study, we confirmed that ROCK inhibitor is able to enhance
adhesion and wound healing on human corneal endothelial cells.
Furthermore, we demonstrated that inhibition of ROCK signaling
enhanced endothelial wound closure in a proliferation-indepen-
dent manner, confirming previous results of this study and strongly
suggesting that cell migration primarily accounted for the observed
effect. Migration process involved membrane protrusion through
cytoskeleton modification and establishment of new adhesion sites
with the substratum over which it migrated. Our study revealed
that inhibition of ROCK signaling induced a morphological
change of HCEC, characterized by a loss of the polygonal shape
and a remodeling of the cytoskeleton, as shown by the re-
distribution of actin on the periphery of the cells and the formation
of circular membrane ruffles. The ability of ROCK to control cells
migration and adhesion of corneal endothelial cells seems to be
related to its role in the regulation of the dynamic rearrangements
of the actin cytoskeleton. Further investigations should be
performed to better understand the mechanisms involved in the
enhancement of wound healing and adhesion by ROCK inhibitor.
In summary, ROCK inhibitor did not shown any toxicity, but is
not the key compound allowing inducing proliferation or limiting
apoptosis of HCEC in eye banking culture system. ROCK
signaling negatively regulates adhesion and wound healing in
human corneal endothelial cells, via modulating the cytoskeleton.
Our results strongly suggest that ROCK inhibitor could be used in
clinic for corneal endothelium dysfunction, either as a direct
treatment for wound healing with eye drop or for cell trans-
plantation by modulation of the cell adhesion properties.
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